Active Ingredient History
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Airway Management (Phase 3)
Angioedema (Phase 2)
Asthma ()
Bronchitis (Phase 4)
Chronic Urticaria (Early Phase 1)
Churg-Strauss Syndrome (Phase 3)
Cough (Phase 4)
COVID-19 (Phase 2/Phase 3)
Dermatitis, Atopic (Phase 2)
Eosinophilia (Phase 2/Phase 3)
Eosinophilic Esophagitis (Phase 2)
Eosinophilic Granuloma (Phase 3)
Eosinophils (Phase 2)
Esophagitis (Phase 2)
Gastroenteritis (Phase 2)
Healthy Volunteers (Phase 1)
Hypereosinophilic Syndrome (Phase 3)
Malaria, Falciparum (Phase 1)
Nasal Polyps (Phase 3)
Pemphigoid, Bullous (Phase 2)
Pharmacokinetics (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Virus Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
